Nivedita BHARDWAJ, Diksha CHOUDHARY, Akashdeep PATHANIA, Somesh BARANWAL, Pradeep KUMAR

2715

Synthesis and molecular docking studies of quinoline derivatives as HIV non-nucleoside reverse transcriptase inhibitors

Synthesis and molecular docking studies of quinoline derivatives as HIV non-nucleoside reverse transcriptase inhibitors

Quinoline moiety is an important scaffold in the field of drug discovery and drug development, with a wide range of pharmacological activities. Quinoline derivatives are potent inhibitors for reverse transcriptase, which is responsible for the conversion of single-stranded viral RNA into double-stranded viral DNA.In the present study, we have designed and synthesized 2 series, namely pyrazoline and pyrimidine containing quinoline derivatives as non nucleoside reverse transcriptase inhibitors (NNRTIs). Eleven compounds were synthesized and characterized by $^{1}H and ^{13}C$ NMR and mass spectrophotometry. The synthesized compounds were also docked on an HIV reverse transcriptase binding site (PDB: 4I2P); most of these compounds showed good binding interactions with the active domain of the receptor. Most of the compounds displayed a docking score higher than those of standard drugs. Among the synthesized quinoline derivatives, compound 4 exhibited the highest docking score (–10.675).
PDF

___

  • 1. Study G, Collaboration PHC. Nucleoside reverse transcriptase inhibitor backbones and pregnancy outcomes. AIDS 2019; 33 (2): 295.
  • 2. Cullen MD, Deng B-L, Hartman TL, Watson KM, Buckheit RW et al. Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability. Journal of Medicinal Chemistry 2007; 50 (20): 4854-4867.
  • 3. Prajapati DG, Ramajayam R, Yadav MR, Giridhar R. The search for potent, small mlolecule NNRTIs: a review. Bioorganic & Medicinal Chemistry 2009; 17: 5744-5762.
  • 4. Kumar S, Kaushik A, Narasimhan B, Shah SAA, Lim SM et al. Molecular docking, synthesis and biological significance of pyrimidine analogues as prospective antimicrobial and antiproliferative agents. BMC Chemistry 2019; 13: 85. doi: 10.1186/s13065-019-0601-z
  • 5. Hameed A, Abdullah MI, Ahmed E, Sharif A, Irfan A et al. Anti-HIV cytotoxicity enzyme inhibition and molecular docking studies of quinoline based chalcones as potential non-nucleoside reverse transcriptase inhibitors (NNRT). Bioorganic Chemistry 2016; 65: 175-182.
  • 6. De Clercq E, Li G. Approved antiviral drugs over the past 50 years. Clinical Microbiology Reviews 2016; 29 (03): 695-747.
  • 7. Genin MJ, Biles C, Keiser BJ, Poppe SM, Swaney SM et al. Novel 1,5-diphenylpyrazole nonnucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3-and 4-substituted derivatives. Journal of Medicinal Chemistry 2000; 43 (5): 1034-1040.
  • 8. Boyer J, Arnoult E, Médebielle M, Guillemont J, Unge J et al. Difluoromethylbenzoxazole pyrimidine thioether derivatives: a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Journal of Medicinal Chemistry 2011; 54 (23): 7974-7985.
  • 9. Melo BC, Bernardino AM, Polillo G, Pereira HS, Paixão IC et al. Novel 4‐arylaminoquinoline‐3‐carbonitriles as inhibitors of HIV‐1 reverse transcriptase. Journal of Heterocyclic Chemistry 2017; 54 (6): 3051-3055.
  • 10. Cai Y, Liu H, Chen H. Allosteric mechanism of quinoline inhibitors for HIV RT‐associated RN ase with MD simulation and dynamics fluctuation network. Chemical Biology & Drug Design 2018; 91 (3): 805-816.
  • 11. George A, Gopi Krishna Reddy A, Satyanarayana G, Raghavendra NK. 1, 2, 3, 4‐Tetrahydroisoquinolines as inhibitors of HIV‐1 integrase and human LEDGF/p75 interaction. Chemical Biology & Drug Design 2018; 91 (6): 1133-1140.
  • 12. Lee H-Y, Nepali K, Huang F-I, Chang C-Y, Lai M-J et al. (N-Hydroxycarbonylbenylamino) quinolines as selective histone deacetylase 6 inhibitors suppress growth of multiple myeloma in vitro and in vivo. Journal of Medicinal Chemistry 2018; 61 (3): 905-917.
  • 13. Jin K, Yin H, De Clercq E, Pannecouque C, Meng G et al. Discovery of biphenyl-substituted diarylpyrimidines as non-nucleoside reverse transcriptase inhibitors with high potency against wild-type and mutant HIV-1. European Journal of Medicinal Chemistry 2018; 145: 726-734.
  • 14. Jin K, Sang Y, De Clercq E, Pannecouque C, Meng G. Design and synthesis of a novel series of non-nucleoside HIV-1 inhibitors bearing pyrimidine and N-substituted aromatic piperazine. Bioorganic & Medicinal Chemistry Letters 2018; 12 (6): 120-136.
  • 15. Wang L, Tang J, Huber AD, Casey MC, Kirby KA et al. 6-Biphenylmethyl-3-hydroxypyrimidine-2, 4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H. European Journal of Medicinal Chemistry 2018; 156: 680-691.
  • 16. ŠimonP, Baszczyňski O, Šaman D, Stepan G, Hu E et al. Novel (2, 6-difluorophenyl)(2-(phenylamino) pyrimidin-4-yl) methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1. European Journal of Medicinal Chemistry 2016; 122: 185-195.
  • 17. Romeo R, Iannazzo D, Veltri L, Gabriele B, Macchi B et al. Pyrimidine 2, 4-diones in the design of new HIV RT inhibitors. Molecules 2018; 24 (9): 1718.
  • 18. Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E et al. 2-(2, 6-Dihalophenyl)-3-(pyrimidin-2-yl)-1, 3-thiazolidin-4-ones as nonnucleoside HIV-1 reverse transcriptase inhibitors. Antiviral Research 2004; 63 (2): 79-84.
  • 19. Tekale AS, Mukhedker SS, Shaikh SAL. A highly efficient synthesis of 2-chloro -3-formyl8-methyl quinoline: Vilsmeier-haack reagent. International Journal of Chemical Studies 2015; 2 (6): 42-45.
  • 20. Gaonkar SL, Vignesh UN. Synthesis and pharmacological properties of chalcones: a review. Research on Chemical Intermediates 2017; 43: 6043-6077.
  • 21. Tomma JH, Khazaal MS, Al-Dujaili AH. Synthesis and characterization of novel Schiff bases containing pyrimidine unit. Arabian Journal of Chemistry 2014; 7: 157-163.
  • 22. Siddiqui ZN, Asad M, Praveen S. Synthesis and biological activity of heterocycles from chalcone. Medicinal Chemistry Research 2008; 17: 318-325.
  • 23. Driessche GVD, Fourches, D. Adverse drug reactions triggered by the common HLA-B57:01 variant: a molecular docking study. Journal of Cheminformatics 2017; 9 (13): 1-17.
  • 24. Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols and influence on virtual screening enrichments. Journal of Computer-Aided Molecular Design 2013; 27 (3): 221-234.
  • 25. Kumar S, Singh J, Narasimhan B, Shah SAA, Lim SM et al. Reverse pharmacophore mapping and molecular docking studies for discovery of GTPase HRas as promising drug target for bis-pyrimidine derivatives. Chemistry Central Journal 2018; 12 (106): 1-11.
  • 26. Sharma V, Sharma PC, Kumar V. In silico molecular docking analysis of natural pyridoacridines as anticancer agents. Advances in Chemistry 2016; 1-9. doi: 10.1155/2016/5409387
  • 27. Singh J, Kumar M, Mansuri R, Sahoo GC, Deep A. Inhibitor designing, virtual screening and docking studies for methyltrans-ferase: a potential target against dengue virus. Journal of Pharmacy and Bioallied Sciences 2016; 8 (3): 188-194.
  • 28. Friesner RA, Murph RB, Repasky MP, Frye LL, Greenwood JR et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein–ligand complexes. Journal of Medicinal Chemistry 2006; 49: 6177-6196.
  • 29. Lenselink EB, Louvel J, Forti AF, Van Veldhoven JPD, De Vries Het al. Predicting binding affinities for GPCR ligands using free-energy perturbation. ACS Omega 2016; 1: 293-304.
  • 30. Nandhakumar R, Suresh T, Jude AC, Mohan P. Synthesis, antimicrobial activities and cytogenetic studies of newer diazepino quinoline derivatives via Vilsmeier–Haack reaction. European journal of Medicinal Chemistry 2007; 42 (8): 1128-1136.
  • 31. Hamama WS, Ibrahim ME, Gooda AA, Zoorob HH. Recent advances in the chemistry of 2-chloroquinoline-3-carbaldehyde and related analogs. RSC Advances 2018; 8: 8484-8515.
  • 32. Dhakshinamoorthy A, Alvaro M, Garcia H. Claisen–Schmidt condensation catalyzed by metal‐organic frameworks. Advanced Synthesis & Catalysis 2010; 352 (4): 711-717.
  • 33. Pawar VS, Lokwani DK, Bhandari SV, Bothara KG, Chitre TS et al. Design, docking study and ADME prediction of isatin derivatives as anti-HIV agents. Medicinal Chemistry Research 2011; 20: 370-380.
Turkish Journal of Chemistry-Cover
  • ISSN: 1300-0527
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK
Arşiv
Sayıdaki Diğer Makaleler

Nivedita BHARDWAJ, Diksha CHOUDHARY, Akashdeep PATHANİA, Somesh BARANWAL, Pradeep KUMAR

Biosynthesis of silver nanoparticles using Onosma sericeum Willd. and evaluation of their catalytic properties and antibacterial and cytotoxic activity

Selda DOĞAN ÇALHAN, Mustafa GÜNDOĞAN

Tokuma GETAHUN, Vinit SHARMA, Deepak KUMAR, Neeraj GUPTA

Huseyin BAS, Nuran KAHRİMAN, Zekeriya BİYİKLİOGLU

Nasrin ALİASGHARLOU, Farzin ASGHARİ SANA, Saba KHOSHBAKHT, Pezhman ZOLFAGHARİ, Hamed CHARKHİAN

Selda DOGAN CALHAN, Mustafa GUNDOGAN

Esin AKYUZ, Sercan TURKOGLU, Kevser SOZGEN BASKAN, Esma TUTEM, Mustafa Resat APAK

Ozlem AKGUL, Mumin Alper ERDOGAN, Dervis BİRİM, Cagla KAYABASİ, Cumhur GUNDUZ, Guliz ARMAGAN

Ishak ERİK, Gözde KILIÇ, Elif ÖZTÜRK, Şengül Alpay KARAOĞLU, Nurettin YAYLI

Innovational combination of hetero-bifunctional N-PEG quinoline scaffolds derivatives with improved anticancer activity against breast and colon cancer cell lines and P-glycoprotein, cytochrome p450 enzyme activity prediction

Mahesh GAIDHANE, Ajay GHATOLE, Kushal LANJEWAR, Kishor HATZADE